Product Images Metformin Hydrochloride

NOC 68645-584-59 is a medication called Metformin Hydrochloride. The tablet has strength of 1000 mg. It can only be dispensed for prescription use. The usual dosage of the medication may be determined by a healthcare professional. The medication should not be accessible to children and should be kept away from them. The manufacturer is located in Bentonville, AR 72716.*

Metformin Hydrochloride Tablets, USP of 500 mg, with 60 tablets per container, manufactured by Granules il Limied and made in India. The medication should be kept out of the reach of children and should be dispensed without patient information. The image contains obscured characters and the failed to recognize any relevant information.*

This is a medication called Metformin Hydrochloride, which comes in tablets of 850mg. The medication should be kept in a light-resistant container and away from children. The prescription is labeled for "Rx only." The text also includes a reference number: "11670 R0 M."*

This text appears to be a table displaying the percentage of side effects experienced by patients taking Metformin Hydrochloride Tablets compared to a placebo. The table lists different symptoms such as Diarrhea, Nausea/Vomiting, Flatulence, Asthenia, Indigestion, Abdominal discomfort, and a Headache. For each symptom, the table displays the percentage of patients experiencing the symptom for both the Metformin group (n=141) and the placebo group (n=145).*

This appears to be a table showing the dosage and efficacy of Metformin Hydrochloride tablets of 500mg, 7000mg, and 1500mg. The tablets are taken either twice daily or once daily. The efficacy is measured by Hemoglobin A1c% and FPG (fasting plasma glucose) in a sample size of 67-72 individuals. The table shows the baseline measurement and the change at the final visit, along with its 95% confidence interval.*

This excerpt discusses the potential interactions and impacts of various drugs and substances when taken with Metformin Hydrochloride Tablets, a drug used for the treatment of type 2 diabetes. It highlights the possible risks of using Carbonic Anhydrase Inhibitors and drugs that can reduce the clearance of Metformin Hydrochloride Tablets, and advises patients to use alcohol cautiously. It also cautions users about the potential risks of combining Metformin Hydrochloride Tablets with certain insulin secretagogues, and other drugs that may affect glycemic control.*

This is a table showing the renal clearance and dose of Metformin Hydrochloride Tablet for different subject groups. It includes healthy, nondiabetic adults; adults with type 2 diabetes mellitus; elderly healthy nondiabetic adults; and renal-impaired adults with mild, moderate or severe impairment. For each group, the table indicates the number of subjects, dose, renal clearance, and hours for one dose.*

This text appears to be a table of co-administered drugs and their doses, with a "geometric mean ratio" indicating the effect of administering them with metformin. Additionally, there is information indicating that no dosing adjustments are required for various medications, including glyburide, furosemide, nifedipine, propranolol, ibuprofen, and cimetidine, when taken with 850mg of metformin.*

This is a table showing the results of a study comparing Metformin Hydrochloride tablets to a placebo for patients with high levels of FPG and Hemoglobin A1c. The number of patients in the study for each medication is listed in parentheses. The table shows the baseline levels and the change in levels at the final visit for each variable. The p-values are also included.*

The text provides statistical values for the treatment groups of a clinical study evaluating the effects of a combination of drugs on fasting plasma glucose and hemoglobin A1c levels. The drug combination includes Glyb and Met. The text includes p-values comparing different treatment groups for the baseline and final visit measurements. There are also some NS* values indicating that certain p-values were not significant.*

This is a table presenting the results of a study involving Metformin Hydrochloride tablets and placebo on subjects with a certain health condition as indicated by the values in the "FPG (mg/dL)" column. The table shows the number of participants in each group ("n=37" and "n=36"). The "Baseline" row indicates the initial values for each group. The "Change at FINAL VISIT" row indicates the final values after the study period. The number "429" in the Metformin Hydrochloride group and "214" in the Placebo group suggest a significant difference between the two groups, given the p-value of "<0001".*